Application Value of Sacubitril Valsartan Sodium in Patients after Acute Myocardial Infarction Intervention
Objective To explore the application value of sacubitril valsartan sodium in patients after acute myocardial infarction(AMI)intervention.Methods 70 AMI patients admitted to our hospital from May 2022 to April 2023 were divided into two groups according to lottery method.The observation group was treated with sacubitril valsartan sodium,and the control group was treated with enalapril.The cardiac function,serum indicators and prognosis were compared between the two groups.Results After treatment,the LVESD and LVEDD of the two groups decreased,the LVEF increased(P<0.05);The LVESD and LVEDD of the observation group were lower than those of the control group,and the LVEF was higher than that of the control group(P<0.05).After treatment,the NT-proBNP and CK-MB levels of the two groups decreased,and the NT-proBNP and CK-MB levels of the observation group were lower than those of the control group(P<0.05).The incidence of MACE in observation group was 11.43%,lower than 31.43%in the control group(P<0.05).Conclusions Early application of sacubitril valsartan sodium can prevent myocardial remodeling after AMI intervention,protect the cardiac function and improve prognosis.
国家科技期刊平台
NSTL
万方数据
维普
